From: Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review
Surgery type | Author and year | Comparator and patients per arm (n) | Primary endpoint | Principal results |
---|---|---|---|---|
Gynaecologic surgery | Angioli 2009[23] | Floseal® (8) | Control of minor bleeding | Not significant differences in the time to haemostasis, blood loss, or the operating time. |
Control (bipolar forceps or carbon-dioxide laser) (12) | ||||
Raga 2009[24] | Floseal® (25) | Haemostatic efficacy | Less intra- and postoperative blood loss (p = 0.001) and a lower rate of transfusions (0% in the Floseal® group) (p < 0.001) for patients treated with Floseal®. A shorter length of hospital stay in the Floseal® group (p = 0.005). | |
Isotonic sodium chloride (25) | ||||
Sönmezer 2013[25] | Floseal® (13) | Ovarian reserve and damage | During the first postoperative month, ovarian damage was significantly lower in the Floseal® group (p < 0.001). However, at the third month after surgery, NS differences were found. | |
Bipolar electrosurgical coagulation (15) | ||||
Lacrimal surgery | Durrani 2007 | Floseal® (10) | Postoperative bleeding and patient comfort | Nine patients in the Floseal® group had no or minimal bleeding; this finding was statistically significant at all three measured time points (immediately (p = 0.047), at 12 h (p = 0.006), and at 24 h after surgery (p = 0.005)). The Floseal® group also had less postoperative discomfort (p = 0.0001). |
Without Floseal® (10) | ||||
Thyroid surgery | Testini 2009[22] | Floseal® (54) | Operating time and wound drain removal | A significantly shorter operating time in the Floseal® group than in the other groups (p < 0.05). More rapid wound drain removal and a shorter length of hospital stay in the Floseal® group compared with the other groups (p < 0.05 both). Not significant difference in postoperative morbidity. |
Surgical haemostasis (49) | ||||
Tabotamp (52) |